Form 4: Heron Therapeutics Executive Acquires Shares

Heron Therapeutics Chief Operating Officer Mark Hensley acquired 125,000 restricted stock units on May 6, 2026.

Summary

• Mark Hensley, Chief Operating Officer of Heron Therapeutics, Inc., acquired 125,000 restricted stock units (RSUs) on May 6, 2026.
• These RSUs represent a contingent right to receive one share of common stock.
• Following this transaction, Hensley beneficially owns 136,770 shares of common stock.
• The RSUs vest over time, with 25% vesting on the first anniversary of the grant date (May 6, 2025) and the remainder vesting in twelve equal quarterly installments thereafter.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents a standard executive compensation and incentive mechanism rather than a significant strategic move or financial performance indicator.

Positives

• Executive leadership participation in equity ownership through RSUs can signal confidence in the company's future prospects.
• The acquisition of RSUs by the COO indicates a commitment to long-term value creation.

Future Outlook

The vesting schedule of the restricted stock units suggests a long-term incentive structure for the Chief Operating Officer, aligning his interests with the company's sustained performance.

Industry Context

StockSavvy.ai notes that insider acquisitions of equity, particularly through RSUs with vesting schedules, are common in the biotechnology and pharmaceutical sectors as a means to attract and retain executive talent and align their interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The acquisition of RSUs by a key executive can be viewed positively as it aligns executive interests with long-term shareholder value.
• Employees: May signal stability and continued investment in leadership.
• Management: Reinforces the incentive structure for executive performance.

Next Steps

• Continued vesting of restricted stock units according to the established schedule.
• Potential future transactions by Mark Hensley related to his beneficial ownership.

Key Dates

Keywords

Heron Therapeutics, HRTX, Form 4, Insider Transaction, Restricted Stock Units, Executive Compensation, Beneficial Ownership